Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Usual Care Clear all
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 30, 2026, 2:16 AM EDT
Active, not recruiting Phase 4 Interventional

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

NCT06372496
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
36
States / cities
Centreville, Alabama • Little Rock, Arkansas • Newport Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 30, 2026, 2:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services

NCT02517554
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer
Interventions
Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site, Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site, Patient receives written information on how to find genetic services in their area
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
7
States / cities
Elkton, Maryland • Cape May Court House, New Jersey • Sewell, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Sep 30, 2026, 2:16 AM EDT
Completed No phase listed Observational

Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment

NCT02917057
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide once weekly, basal insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
6,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 30, 2026, 2:16 AM EDT
Not listed Phase 3 Interventional

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00719303
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Behavioral Dietary Intervention, Compliance Monitoring, Counseling, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
687
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 30, 2026, 2:16 AM EDT
Withdrawn Phase 4 Interventional

Effectiveness of Aurix Therapy in Venous Leg Ulcers

NCT02940587
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Aurix
Device
Lead sponsor
Cytomedix
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care

NCT00703963
View directory record Official record
Conditions
Management of Anticoagulation
Interventions
INRatio monitor by Hemosense, Usual Care
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Results available

Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy

NCT00993200
View directory record Official record
Conditions
Blood Clotting
Interventions
warfarin pharmacogenetic dosing, Warfarin
Genetic · Drug
Lead sponsor
Robert Pendleton
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 30, 2026, 2:16 AM EDT
Terminated Not applicable Interventional

STEPs to Blood Pressure Reduction.

NCT02591394
View directory record Official record
Conditions
Stroke Prevention, Blood Pressure Reduction
Interventions
STEP Clinic, Usual Care
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 30, 2026, 2:16 AM EDT
Withdrawn Not applicable Interventional

Tracheostomy With Bedside Simultaneous Gastrostomy Vs Usual Care Tracheostomy And Delayed Gastrostomy Placement

NCT04758052
View directory record Official record
Conditions
Stroke, Acute, TBI, Neuromuscular Diseases, Status Epilepticus, Coma, Cerebrovascular Disorders, Spinal Cord Injuries, Neurological Injury, Neurologic Injury
Interventions
Timing of placement
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Not applicable Interventional

Healthy Transitions in Late Stage Kidney Disease

NCT02085837
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Education, Daily weight measurement and monitoring, Universal Dietary education, Medication review, Focused advanced directive program, Countdown to fistula program
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 30, 2026, 2:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

NCT05674799
View directory record Official record
Conditions
Overweight or Obesity
Interventions
NDPP-NextGen
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Phase 4 Interventional

Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure

NCT01863511
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
loop diuretic, tolvaptan, ultrafiltration
Drug · Procedure
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC

NCT04030130
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
NDURE
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 30, 2026, 2:16 AM EDT
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

NCT02957136
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions
Rapid respiratory pathogen nucleic acid amplification test
Device
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 101 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Sep 30, 2026, 2:16 AM EDT
Completed No phase listed Observational

The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

NCT03631225
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Vectra
Diagnostic Test
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
La Mesa, California • Murrieta, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Validation of the STarT Back Screening Tool in the Military

NCT03127826
View directory record Official record
Conditions
Low Back Pain, Lumbago, Radiculopathy, Intervertebral Disc Disorder
Interventions
Risk Stratified Care, Usual Care
Procedure
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 30, 2026, 2:16 AM EDT
Not listed Not applicable Interventional

Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease

NCT01427218
View directory record Official record
Conditions
Coronary Heart Disease, Myocardial Infarction
Interventions
Titration of medications, Lifestyle Counseling, Medication Counseling, Usual Care with Medication Reconciliation
Other · Behavioral
Lead sponsor
Middle Tennessee Research Institute
Other
Eligibility
60 Years to 90 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 30, 2026, 2:16 AM EDT
Completed No phase listed Observational

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers

NCT00684801
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Motivational Interviewing and Guided Opioid Tapering Support to Promote Postoperative Opioid Cessation

NCT03659734
View directory record Official record
Conditions
Opioid Cessation
Interventions
Motivational Interviewing and Guided Opioid Tapering Support, Enhanced Usual Care
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Research on Improving Sleep During Pregnancy

NCT05017974
View directory record Official record
Conditions
Sleep, Pregnancy Related
Interventions
Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement, Treatment as Usual
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Sep 30, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

NCT01131676
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 low dose, Placebo BI 10773 high dose, BI 10773 high dose, Placebo BI 10773 low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
7,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
170
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 30, 2026, 2:16 AM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

NCT07504588
View directory record Official record
Conditions
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 2:16 AM EDT